Azaya Therapeutics expands operations with roll out of Parexo Labs

http://www.bizjournals.com/sanantonio/blog/2013/07/azaya-therapeutics-expands-operations.html

Jul 8, 2013, 11:16am CDT

W. Scott Bailey

Azaya Therapeutics expands operations with roll out of Parexo Labs

Here a few of them: cheap viagra overnight Lean beef: Red meats such as ground beef are an excellent source of protein. X-ray aimhousepatong.com commander cialis will help the cardiologist to position the catheter. This drug starts effecting after 45-50 minutes and remains effective cialis 5mg sale for about 4 hours. Men aged 35 to 45, having a BMI of >25 and especially those with a BMI of cialis pill from india >30 exhibit a poorer ovarian response to fertility drugs (impaired follicle and embryo development with fewer blastocysts becoming available for transfer). Azaya Therapeutics has created a new division that can perform contract development and manufacturing on behalf of outside firms.

Azaya Therapeutics Inc. has launched a new division called Parexo Labs. The new entity will operate as a contract development and manufacturing organization, and will provide chemical testing and liposomal manufacturing services to outside organizations.

San Antonio-based Azaya is a privately held oncology company focused on developing more effective cancer treatments through its nanotechnology platform. Parexo Labs will leverage Azaya’s twin capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including its proprietary analytical methodology, to detail release rates and characterization attributes of nanoparticles.

“Azaya Therapeutics has over 10 years of experience in the cytotoxic and nanotechnology arenas, which we are now leveraging with the roll out of Parexo Labs,” says Azaya President and CEO Mike Dwyer. “Through Parexo, we can apply these analytical capabilities and development methodologies to organizations in need of them for their own development programs.”

Azaya Therapeutics Announces Launch of CDMO, Parexo Labs

Oncology firm Azaya Therapeutics Inc. has announced the formation of a new division that will provide liposomal manufacturing services and chemical testing. The new division will be known as Parexo Labs and is also a CDMO, or contract development and manufacturing organization.

Azaya itself has been busy developing alternative methods for battling cancer through nanotechnology. While still a nascent technology, nanotechnology is currently a hot subject in clinical trials, and companies like Azaya hope to use the method to revolutionize how drugs are delivered to patients in fields like oncology.

It helps in improving female fertility as generic levitra pill well. This quality of healthy, firm and sturdy http://secretworldchronicle.com/books/ cialis generika erection gives a user pleasurable lovemaking time with their partners. These foods replenish the secretworldchronicle.com viagra pill for sale skeletal needs of the body. So, walk about half an hour to decrease about 41% possibility of the risk of ED. cialis in australia The launch of Parexo Labs by Azaya is designed to give the San Antionio-based biotech company the assets necessary to expand further into nanotechnology and other related technologies. A press release recently published by The Wall Street Journal reveals that:

…Parexo Labs leverages Azaya’s twin capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including its proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles. Parexo Labs offers laboratory services that can speed drug development and regulatory progress for pharmaceutical and medical device developers alike…Parexo Labs services cover method development and validation for cytotoxics, as well as raw material testing, stability storage and testing, chemical characterization and other analyses. Parexo also provides customized liposome manufacturing services, based on its proprietary nanoparticle release methodology, to meet customers’ academic or commercial needs.

Parexo-Labs-Logo“Azaya Therapeutics has over ten years of experience in the cytotoxic and nanotechnology arenas, which we are now leveraging with the rollout of Parexo Labs,” Azaya’s CEO and President Mike Dwyer explains.”Through Parexo, we can apply these analytical capabilities and development methodologies to organizations in need of them for their own development programs.” San Antonio-based Azaya, which is a privately held company that was founded in 2003, has held the patent for their PSL (Protein Stabilized Liposome) nanotechnology since 2007 and is working to use this technology in conjunction with liposomes to development new treatments for various cancers.